- Home
- GNFT vs AVIR Comparison
GNFT vs AVIR Comparison
Compare GNFT & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- AVIR
- Stock Information
- Founded
- GNFT 1999
- AVIR 2012
- Country
- GNFT France
- AVIR United States
- Employees
- GNFT N/A
- AVIR N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- GNFT Health Care
- AVIR Health Care
- Exchange
- GNFT Nasdaq
- AVIR Nasdaq
- Market Cap
- GNFT 190.6M
- AVIR 247.5M
- IPO Year
- GNFT 2019
- AVIR 2020
- Fundamental
- Price
- GNFT $3.71
- AVIR $3.29
- Analyst Decision
- GNFT Strong Buy
- AVIR Hold
- Analyst Count
- GNFT 1
- AVIR 1
- Target Price
- GNFT $13.00
- AVIR $6.88
- AVG Volume (30 Days)
- GNFT 7.9K
- AVIR 510.6K
- Earning Date
- GNFT 09-19-2024
- AVIR 11-07-2024
- Dividend Yield
- GNFT N/A
- AVIR N/A
- EPS Growth
- GNFT N/A
- AVIR N/A
- EPS
- GNFT 0.47
- AVIR N/A
- Revenue
- GNFT $86,225,222.00
- AVIR N/A
- Revenue This Year
- GNFT $155.44
- AVIR N/A
- Revenue Next Year
- GNFT N/A
- AVIR N/A
- P/E Ratio
- GNFT $7.55
- AVIR N/A
- Revenue Growth
- GNFT 175.45
- AVIR N/A
- 52 Week Low
- GNFT $3.31
- AVIR $2.75
- 52 Week High
- GNFT $6.42
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- GNFT 33.06
- AVIR 55.51
- Support Level
- GNFT $3.63
- AVIR $3.10
- Resistance Level
- GNFT $3.94
- AVIR $3.32
- Average True Range (ATR)
- GNFT 0.13
- AVIR 0.14
- MACD
- GNFT 0.03
- AVIR 0.04
- Stochastic Oscillator
- GNFT 19.17
- AVIR 95.58
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).